Conduct↦Ethics and Laws↦Participant Protection↦Consent of Vulnerable Participants
What is it? Why is it important?
A “vulnerable participant” is any individual who lacks the ability to fully decide or consent to study participation. Studies with vulnerable participants require that it is not possible to obtain equivalent findings from non-vulnerable subjects.
Additional procedures ensure that the rights of these participants are protected, such as to:
- Clarify whether the study:
- Involves more than “minimal risks and burdens”?
- Has an expected direct benefit for participants?
- Expects to generate substantial findings?
- Seek consent from legal representative(s) or relative(s)
- Request the opinion of a study- independent physician (e.g. studies in emergency situations)
- Adapt the Participant Information Sheet (PIS) / Informed Consent Form (ICF) to suit children or adolescents
- Confirm that vulnerable participants do not visibly express an opposition to study participation (e.g. verbally or through behaviour)
More
Vulnerable participants include
- Children, adolescents, persons lacking capacity, persons in emergency situations, pregnant & breastfeeding women and their foetus or infant, prisoners.
Based on the law, special informed consent procedures apply for vulnerable participants
Special requirements for the recruitment of vulnerable participants
Children with capacity participating in a study with an expected direct benefit:
- Informed consent of the child
- Written consent of the legal representative
Children with capacity participating in a study without expected direct benefit:
- Informed consent of the child
- Written consent of the legal representative
- The study entails no more than minimal risks and burdens
- Study data is expected to benefit future children with the same disease or situation
Children lacking capacity participating in study with expected direct benefit:
- Written consent of the legal representative
- The child does not visibly express opposition verbally or through his/her behaviour
Children lacking capacity participating in a study without expected direct benefit:
- Written consent of the legal representative
- The child does not visibly express opposition verbally or through his/her behaviour
- The study entails no more than minimal risks and burdens
- Study data is expected to benefit future children with the same disease or situation
Adolescents with capacity participating in as study with or without expected direct benefit:
- Adolescent written informed consent
- If the study entails more than minimal risks and burdens, requires a written consent of the legal representative
Adolescents lacking capacity participating in a study with an expected direct benefit:
- Written consent of the legal representative
- Adolescent does not visibly express opposition verbally or through his/her behaviour
Adolescents lacking capacity participating in a study without expected direct benefit:
- Similar to expected benefit, and
- The study entails no more than minimal risks and burdens
- Study data is expected to benefit future adolescents with the same disease or situation
What do I need to do?
As a SP-INV or Site-INV recruiting vulnerable study participants :
- Take necessary measures to safeguard their specific rights and welfare
- During study conduct ensure to seek additional consent from participants in the event:
- Children/adolescents reach legal age of maturity
- Adults regain capacity to consent (e.g. post-hoc consent in emergency situation studies)
- Exclude participants from study participation who show signs of objection (e.g. verbally or through participant behaviour), even if the legal representative gives consent
Participants not able to provide consent prior to study inclusion (e.g. emergency setting), must be provided the opportunity as soon as feasible (e.g. post-hoc consent). In the event the emergency participant refuses post-hoc consent, destroy already collected data and Biological Material (BM).
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
External Links
Swissethics – see in particular under "Topics"
- Research with children and adolescents
References
Declaration of Helsinki – see in particular principles
- 19-20 Vulnerable groups and individuals
ISO 14155:2020 Medical Devices (access liable to costs) – see in particular sections and annex
- 5.7 Vulnerable populations
- 5.8.3 Special circumstances for informed consent
- 7.7 Subject privacy and confidentiality of data
- 10.7 Medical care of subjects Respect of participants
- Annex A Vulnerable population (A.15)
SAMS manual Research with human subjects – see in particular chapters
- Chapter 5 Research with children and adolescents
- Chapter 8 Information and consent
- Chapter 9 Respect of participants
Swiss Law
HRA – see in particular articles
- Art. 11 Subsidiarity
- Art. 21-24 Research involving Children, Adolescents and Adults lacking Capacity
- Art. 25-27 Research involving Pregnant Women and Embryos and Foetuses in vivo
- Art. 28-29 Research involving Prisoners